Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications

Journal of Psychopharmacology

Volumn 22, Issue 4, 2008, Pages 434-440

  Vanoli, A ^a   Lane, C J ^b   Harrison, Claire ^c   Steen, N I ^d   Young, A H ^e  

^a NORTHUMBRIA UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c TYNE AND WEAR NHS FOUNDATION TRUST   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Cost consequences analysis; Depressed patients; Economics; High dose; Non responders; Venlafaxine

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT; VENLAFAXINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; OUTPATIENT; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; COHORT STUDIES; COST-BENEFIT ANALYSIS; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENGLAND; FEMALE; HOSPITAL COSTS; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES;

EID: 47249146474     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107086178     Document Type: Article

References (29)

1. Anderson, IM, Nutt, DJ, Deakin, JF (2000) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. J Psychopharmacol 14: 3-20.
2. Andrews, G. (2001) Should depression be managed as a chronic disease ? BMJ 322: 419-421.
3. Benkert, O., Grunder, G., Wetzel, H., Hackett, D. (1996) A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 30: 441-451.
4. British Medical Association (2005) BNF 50, MeReC [electronic version]. London: The British Medical Association and the Royal Pharmaceutical Society of Great Britain.
5. Curtis, L., Netten, A. (2005) Unit Costs of Health and Social Care 2005. Canterbury: Personal Social Services Research Unit, University of Kent.
6. Department of Health (2006) NHS Reference Costs 2005-06. London: Department of Health. http://www.dh.gov.uk/en/Publicationsandstatistics/ Publications/PublicationsPolicyAndGuidance/DH_082571.
7. Drummond, M., O'Brien, B., Stoddard, GL, Torrance, GW (1997) Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press.
8. Einarson, TR, Addis, A., Iskedjian, M. (1997) Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder. Pharmacoeconomics 12: 286-296.
9. Freeman, H., Arikian, S., Lenox-Smith, A. (2000) Pharmacoeconomic analysis of antidepressants for major depressive disorder in the United Kingdom. Pharmacoeconomics 18: 143-148.
10. Gerner, R., Estabrook, W., Steuer, J. (1980) Treatment of geriatric depression with trazodone, imipramine and placebo: a double-blind study. J Clin Psychiatry 41: 216-220.
11. Greenhalgh, J., Knight, C., Hind, D., Beverley, C., Walters, S. (2005) Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 9: 170.
12. Gutierrez, MA, Stimmel, GL, Aiso, JY (2003) Venlafaxine: a 2003 update. Clin Ther 25: 2138-2154.
13. Harrison, CL, Ferrier, IN, Young, AH (2001) Tolerability of high dose venlafaxine in depressed patients. ECNP Conference, Barcelona, October 2001.
14. Henry, JA, Rivas, CA (1997) Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: depression and its treatment. Pharmacoeconomics 11: 419-443.
15. Hirschfeld, RM (1999) Efficacy of SSRIs and newer antidepressants in severe depression: comparison with TCAs. J Clin Psychiatry 60: 326-335.
16. Kessler, RC, Berlgund, P., Demler, O., Jin, R., Koretz, D., Merikangas, KR, Rush, AJ, Walters, EE, Wang, PS (2003) The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105.
17. Kind, P., Sorensen, J. (1993) The costs of depression. Int Clin Psychopharmacol 7: 191-195.
18. Mitchell, PB, Schweitzer, I., Burrows, G., Johnson, G., Polonowita, A. (2000) Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Pharmacol 20: 483-487.
19. Möller, HJ, Demyttenaere, K., Sacchetti, E., Rush, AJ, Montgomery, SA (2003) Improving the chance of recovery from the short- and long-term consequences of depression. Int Clin Psychopharmacol 18: 219-225.
20. Murray, CJL, Lopez, AD (1997 a) Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504.
21. Murray, CJL, Lopez, AD (1997 b) Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 349: 1436-1442.
22. Rost, K., Nutting, P., Smith, JL, Elliott, CE, Dickinson, M. (2002) Managing depression as a chronic disease: a randomized trial of ongoing treatment in primary care. BMJ 325: 934.
23. Thase, ME (1997) Efficacy and tolerability of once daily venlafaxine extended release (XR) in outpatients with major depression. J Clin Psychiatry 58: 393-398.
24. Thase, ME, Entsuah, AR, Rudolph, RL (2001) Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 178: 234-241.
25. Thomas, C., Morris, S. (2003) Cost of depression among adults in England in 2000. Br J Psychiatry 183: 514-519.
26. Thompson, C., Thompson, CN (1989) The prescribing of antidepressants in general practice II. A placebo-controlled trial of low-dose dothiepin. Hum Psychopharmacol 4: 191-204.
27. Weissman, MM, Williams, JBW, Spitzer, RL (1984) The psychological treatment of depression: update of clinical trials. In: Williams, JBW, Spitzer, RL, (Eds). Psychotherapy research: where are we and where should we go? New York: Guilford Press, pp. 89-105.
28. Wittchen, HU, Knauper, B., Kessler, RC (1994) Lifetime risk of depression. Br J Psychiatry: 16-22.
29. World Health Organization (2001 c) Mental and Neurological Disorders (fact sheet No. 265, December). Geneva, World Health Organization.